AVVantgarde Bio is a gene therapy startup that has developed two adeno-associated viral (AAV)-based platforms with increased transfer capabilities to enable the delivery of large genes.
Gene therapy based on AAV vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company’s two AAV-based platforms have expanded transfer capability that enable the delivery of large genes.
The company aims to initially focus on using it approach to launch clinical trials of gene therapies for inherited retinal disorders.
Founded in 2021, AAVantgarde Bio originates from research activities performed at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy. Co-founder Professor Alberto Auricchio, is described by the company as a pioneer in the field of gene therapy.
Subscribe for alerts on new companies featured on Startups.Bio
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …